An FDA advisory panel recommended the agency give its approval to an insulin inhalant, Exubera, developed by Pfizer, Nektar Therapeutics and Sanofi-Aventis for diabetics. Pfizer said it was ready to begin a patient-monitoring plan to track the safety of the product, considered by the industry to have sales possibilities of $2 billion a year.

Related Summaries